Howell S, Howell A
Adv Exp Med Biol. 2025; 1464():449-474.
PMID: 39821038
DOI: 10.1007/978-3-031-70875-6_22.
Eissa M, Gohar E
Biomed Pharmacother. 2023; 168:115832.
PMID: 37931519
PMC: 10843764.
DOI: 10.1016/j.biopha.2023.115832.
Pinto C, Markey K, Dix D, Browne P
Toxicol In Vitro. 2017; 47:103-119.
PMID: 29146384
PMC: 7008464.
DOI: 10.1016/j.tiv.2017.11.003.
Lonning P, Eikesdal H
Endocr Relat Cancer. 2013; 20(4):R183-201.
PMID: 23625614
PMC: 3689263.
DOI: 10.1530/ERC-13-0099.
Lonning P
Ann Oncol. 2010; 22(3):503-514.
PMID: 20616198
PMC: 3042921.
DOI: 10.1093/annonc/mdq337.
Aromatase inhibitors: past, present and future in breast cancer therapy.
Dutta U, Pant K
Med Oncol. 2007; 25(2):113-24.
PMID: 17973095
DOI: 10.1007/s12032-007-9019-x.
Aromatase inhibitors for breast cancer.
Briest S, Davidson N
Rev Endocr Metab Disord. 2007; 8(3):215-28.
PMID: 17486453
DOI: 10.1007/s11154-007-9039-z.
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan V, Brodie A
Steroids. 2006; 72(1):7-25.
PMID: 17169390
PMC: 2566956.
DOI: 10.1016/j.steroids.2006.10.009.
Involvement of steroids in anti-inflammatory effects of PK11195 in a murine model of pleurisy.
da Silva M, Farges R, Frode T
Mediators Inflamm. 2004; 13(2):93-103.
PMID: 15203550
PMC: 1781550.
DOI: 10.1080/09629350410001688486.
Clinical pharmacokinetics of aromatase inhibitors and inactivators.
Lonning P
Clin Pharmacokinet. 2003; 42(7):619-31.
PMID: 12844324
DOI: 10.2165/00003088-200342070-00002.
The role of aromasin in the hormonal therapy of breast cancer.
Dank M
Pathol Oncol Res. 2002; 8(2):87-92.
PMID: 12172571
DOI: 10.1007/BF03033716.
Is there a growing role for endocrine therapy in the treatment of breast cancer?.
Lonning P
Drugs. 2000; 60(1):11-21.
PMID: 10929927
DOI: 10.2165/00003495-200060010-00002.
Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.
Njar V, Brodie A
Drugs. 1999; 58(2):233-55.
PMID: 10473018
DOI: 10.2165/00003495-199958020-00003.
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P
Br J Cancer. 1996; 74(8):1286-91.
PMID: 8883419
PMC: 2075919.
DOI: 10.1038/bjc.1996.531.
First generation aromatase inhibitors--aminoglutethimide and testololactone.
COCCONI G
Breast Cancer Res Treat. 1994; 30(1):57-80.
PMID: 7949205
DOI: 10.1007/BF00682741.
Aromatase inhibitor development for treatment of breast cancer.
Masamura S, Adlercreutz H, Harvey H, Lipton A, Demers L, Santen R
Breast Cancer Res Treat. 1995; 33(1):19-26.
PMID: 7749129
DOI: 10.1007/BF00666067.
Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
SAMOJLIK E, Veldhuis J, Wells S, Santen R
J Clin Invest. 1980; 65(3):602-12.
PMID: 6986409
PMC: 371401.
DOI: 10.1172/JCI109705.
Aminoglutethimide treatment in advanced breast cancer: an efficient therapy as a late endocrine alternative in a sequential therapeutic approach.
KVINNSLAND S, Dahl O
Breast Cancer Res Treat. 1983; 3(1):73-6.
PMID: 6871483
DOI: 10.1007/BF01806236.
Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.
Smith I, Harris A, Morgan M, Ford H, Gazet J, Harmer C
Br Med J (Clin Res Ed). 1981; 283(6304):1432-4.
PMID: 6797571
PMC: 1507612.
DOI: 10.1136/bmj.283.6304.1432.
Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer.
Bruning P, Bonfrer J, ENGELSMAN E, Nooyen W
Breast Cancer Res Treat. 1984; 4(4):289-95.
PMID: 6518295
DOI: 10.1007/BF01806041.
